生命早期甲苯达唑暴露增加成年起病溃疡性结肠炎风险:一项基于人群的队列研究
该研究基于丹麦1995至2018年出生人群的队列数据,纳入1,520,290人,其中615,794人有儿童期或青春期甲苯达唑暴露。调整混杂因素后,18岁前甲苯达唑暴露与儿童起病或成年起病IBD风险均无关联;但5岁前暴露与成年起病IBD风险升高相关(aHR 1.17,95%CI 1.04-1.31),该风险升高由溃疡性结肠炎驱动(aHR 1.32,95%CI 1.12-1.55),而克罗恩病无关联(aHR 1.03,95%CI 0.87-1.22)。
要点
- 18岁前甲苯达唑暴露与儿童起病或成年起病IBD风险均无显著关联。
- 5岁前甲苯达唑暴露与成年起病IBD风险升高相关(aHR 1.17,95%CI 1.04-1.31)。
- 5岁前暴露的风险升高由溃疡性结肠炎驱动(aHR 1.32,95%CI 1.12-1.55),克罗恩病无关联。
核心结论
- 生命早期甲苯达唑暴露与成年起病溃疡性结肠炎风险升高相关,提示生命早期暴露对日后IBD风险塑造具有重要意义。
研究设计与样本
- 基于人群的队列研究,利用丹麦1995至2018年出生所有个体的前瞻性收集历史数据。
- 队列共纳入1,520,290人,其中615,794人有儿童期或青春期甲苯达唑暴露。
- 采用调整的Cox比例风险回归分析,评估甲苯达唑暴露后IBD、溃疡性结肠炎和克罗恩病的风险,并调整潜在混杂因素。
主要发现
- 18岁前甲苯达唑暴露与儿童起病IBD风险无关联(aHR 0.97,95%CI 0.87-1.07),与成年起病IBD风险亦无关联(aHR 1.08,95%CI 0.97-1.19)。
- 5岁前甲苯达唑暴露与儿童起病IBD无关联(aHR 0.98,95%CI 0.87-1.11),但与成年起病IBD风险升高相关(aHR 1.17,95%CI 1.04-1.31)。
- 5岁前暴露的风险升高由溃疡性结肠炎驱动(aHR 1.32,95%CI 1.12-1.55),克罗恩病无关联(aHR 1.03,95%CI 0.87-1.22)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: According to the hygiene hypothesis, exposure to parasites may protect against inflammatory bowel disease (IBD). Our aim was to examine the risk of IBD with childhood exposure to mebendazole, a broad-spectrum antihelminthic agent. METHODS: We conducted a population-based cohort study using prospectively collected historical data of all individuals born in Denmark between 1995 and 2018. We identified mebendazole exposure at age younger than 18 years and during early life (younger than 5 years). We performed adjusted Cox proportional hazards regression analysis to determine the risk of IBD, ulcerative colitis (UC), and Crohn's disease with mebendazole exposure after adjusting for potential confounders. RESULTS: Of 1,520,290 individuals in the cohort, 615,794 had childhood or adolescence mebendazole exposure. One thousand five hundred fifty-five and 1,499 individuals were subsequently diagnosed with pediatric-onset and adult-onset IBD, respectively. On multivariable analysis, mebendazole exposure at age younger than 18 years did not affect pediatric-onset or adult-onset IBD risk (adjusted hazard ratio [aHR] 0.97, 95% confidence interval [CI] 0.87, 1.07, and 1.08, 95% CI 0.97, 1.19, respectively). On limiting mebendazole exposure to age younger than 5 years while there was no association with pediatric-onset IBD (aHR 0.98, 95% CI 0.87, 1.11), adult-onset IBD risk was increased (aHR 1.17, 95% CI 1.04, 1.31). This increase in risk was driven by UC (aHR 1.32, 95% CI 1.12, 1.55), but not Crohn's disease (1.03, 95% CI 0.87, 1.22). DISCUSSION: Early-life mebendazole exposure is associated with an increase in the risk of adult-onset UC. These findings suggest the importance of early-life exposures in shaping the risk of IBD later in life.
引用
- Agrawal M, Allin KH, Iversen AT, et al. Early-Life Mebendazole Exposure Increases the Risk of Adult-Onset Ulcerative Colitis: A Population-Based Cohort Study. Am J Gastroenterol. 2022. PMID: 36040420. doi:10.14309/ajg.0000000000001933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。